Table 2.
Univariate and multivariate analyses of factors contributing to overall survival (n=1170).
| Multivariate Analysis | ||||
|---|---|---|---|---|
| Variables | n | Univariate Analysis | Hazard Ratio (95% CI) | P valuea |
| Gender, male vs. female | 724 / 446 | 0.081 | ||
| Age (years), ≥70 vs. <70 | 615 / 555 | 0.175 | ||
| Tumor number, single vs. multiple | 632 / 538 | <0.001 | ||
| Maximum tumor size (cm), ≥2.5 vs. <2.5 | 599 / 571 | <0.001 | ||
| Child-Pugh, A vs. B or C | 804 / 366 | <0.001 | 2.226 (1.877-2.640) | <0.001 |
| HCC stage, I or II vs. III or IV | 753 / 417 | <0.001 | 2.096 (1.883-2.653) | <0.001 |
| Cause of liver disease, Virus related vs. NBNC | 955 / 215 | 0.511 | ||
| Serum sodium (A / B / C) | 96 / 520 / 554 | <0.001 | ||
| Serum sodium >140 mmol/L (group C) | Reference | |||
| 135 mmol/L < serum sodium ≤140 mmol/L (group B) | 0.536 (0.403-0.714) | <0.001 | ||
| Serum sodium ≤135 mmol/L (group A) | 0.518 (0.389-0.690) | <0.001 | ||
| AST (IU/L), ≥57 vs. <57 | 593 / 577 | <0.001 | 0.767 (0.650-0.905) | 0.002 |
| ALT (IU/L), ≥44 vs. <44 | 587 / 583 | 0.132 | ||
| ALP (IU/L), ≥348 vs. <348 | 586 / 584 | <0.001 | 0.675 (0.572-0.796) | <0.001 |
| GGT (IU/L), ≥64 vs. <64 | 590 / 580 | <0.001 | ||
| Platelet count (×104 / mm3), ≥9.2 vs. <9.2 | 590 / 580 | 0.783 | ||
| Diabetes mellitus, yes vs. no | 289 / 881 | 0.478 | ||
| AFP (ng/mL), ≥29.2 vs. <29.2† | 584 / 584 | <0.001 | 0.821 (0.696-0.968) | 0.019 |
| DCP (mAU/mL), ≥55 vs. <55‡ | 580 / 575 | <0.001 | 0.504 (0.424-0.598) | <0.001 |
CI; confidence interval, HCC; hepatocellular carcinoma, NBNC; non B and non C, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphatase, GGT; gamma glutamyl transpeptidase, AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin, a; Cox proportional hazard model, †; missing data, n=2, ‡; missing data, n=15